+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Aggrecanase 2"

Global Arthritic Therapeutic Market Size, Share & Trends Analysis Report By Application (Rheumatoid Arthritis, Psoriatic Arthritis, Osteoarthritis, Ankylosing Spondylitis and Others), By Product Type, By Regional Outlook and Forecast, 2023 - 2030 - Product Thumbnail Image

Global Arthritic Therapeutic Market Size, Share & Trends Analysis Report By Application (Rheumatoid Arthritis, Psoriatic Arthritis, Osteoarthritis, Ankylosing Spondylitis and Others), By Product Type, By Regional Outlook and Forecast, 2023 - 2030

  • Report
  • March 2024
  • 221 Pages
  • Global
From
A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 - Pipeline Review, H1 2020 - Product Thumbnail Image

A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 - Pipeline Review, H1 2020

  • Drug Pipelines
  • February 2020
  • 62 Pages
  • Global
From
  • 2 Results (Page 1 of 1)
Loading Indicator

Aggrecanase 2 is a type of drug used to treat musculoskeletal disorders. It is a type of enzyme that breaks down the aggrecan molecule, which is a major component of cartilage. Aggrecanase 2 is used to treat conditions such as osteoarthritis, rheumatoid arthritis, and other joint diseases. It is believed to reduce pain and inflammation, and improve joint function. The Aggrecanase 2 market is growing due to the increasing prevalence of musculoskeletal disorders. The market is expected to benefit from the development of new drugs and treatments, as well as the increasing awareness of the importance of early diagnosis and treatment. Some of the companies in the Aggrecanase 2 market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Show Less Read more